Prestigious researchers to provide consulting services in connection with abvc biopharma's depression medicines

Fremont, ca, may 23, 2022 (globe newswire) -- via  newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that dr. maurizio fava and dr. thomas laughren have agreed to provide consulting services in connection with clinical studies of its central nervous system medicines designed to alleviate symptoms of major depression disorder (mdd) and adult depression hyperactive disorder (adhd). the company's mdd medicine has successfully completed phase ii clinical studies which were accepted by the u.s. food & drug administration in october 2020. its adhd medicine successfully completed phase ii, part 1 and is initiating part 2 at the university of california, san francisco medical center as well as at five clinical study sites in taiwan.
ABVC Ratings Summary
ABVC Quant Ranking